Paradigm Biopharmaceuticals Ltd has released a press release.
Appendix 4C - September 2016 quarter
Filed with ASX ·
6ix hasn’t read this filing yet.
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- Paradigms Placement heavily oversubscribed
- Preclinical study underpins efficacy of Paradigms RhinosulR
- Paradigm PPS a potential in the treatment of viral arthritis
- Preliminary Final Report
- Paradigm PPS nasal spray to treat Allergic Rhinitis
Later from Paradigm Biopharmaceuticals
- Paradigms hay fever clinical trial cleared to commence
- Recruitment complete in Paradigms hay fever clinical trial
- Quarterly Cashflow Report
- Paradigm Update Ross River Virus Clinical Trial
- Paradigm receives $1.34 million R&D tax incentive rebate
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals